Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

C. Peterfy, P. Emery, PP. Tak, M. Østergaard, J. DiCarlo, K. Otsa, F. Navarro Sarabia, K. Pavelka, MA. Bagnard, LH. Gylvin, C. Bernasconi, A. Gabriele,

. 2016 ; 75 (1) : 170-7. [pub] 20141029

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16021040

OBJECTIVE: To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab treatment in a Phase 3 study of patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) who were naive to biological therapy. METHODS: Patients were randomised to receive two infusions of placebo (n=63), rituximab 500 mg (n=62), or rituximab 1000 mg (n=60) intravenously on days 1 and 15. MRI scans and radiographs of the most inflamed hand and wrist were acquired at baseline, weeks 12 (MRI only), 24 and 52. The primary end point was the change in MRI erosion score from baseline at week 24. RESULTS: Patients treated with rituximab demonstrated significantly less progression in the mean MRI erosion score compared with those treated with placebo at weeks 24 (0.47, 0.18 and 1.60, respectively, p=0.003 and p=0.001 for the two rituximab doses vs placebo) and 52 (-0.30, 0.11 and 3.02, respectively; p<0.001 and p<0.001). Cartilage loss at 52 weeks was significantly reduced in the rituximab group compared with the placebo group. Other secondary end points of synovitis and osteitis improved significantly with rituximab compared with placebo as early as 12 weeks and improved further at weeks 24 and 52. CONCLUSIONS: This study demonstrated that rituximab significantly reduced erosion and cartilage loss at week 24 and week 52 in MTX-inadequate responder patients with active RA, suggesting that MRI is a valuable tool for assessing inflammatory and structural damage in patients with established RA receiving rituximab. TRIAL REGISTRATION NUMBER: NCT00578305.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16021040
003      
CZ-PrNML
005      
20160725112615.0
007      
ta
008      
160722s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2014-206015 $2 doi
024    7_
$a 10.1136/annrheumdis-2014-206015 $2 doi
035    __
$a (PubMed)25355728
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Peterfy, Charles $u Spire Sciences, Inc., Boca Raton, Florida, USA.
245    10
$a MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study / $c C. Peterfy, P. Emery, PP. Tak, M. Østergaard, J. DiCarlo, K. Otsa, F. Navarro Sarabia, K. Pavelka, MA. Bagnard, LH. Gylvin, C. Bernasconi, A. Gabriele,
520    9_
$a OBJECTIVE: To evaluate changes in structural damage and joint inflammation assessed by MRI following rituximab treatment in a Phase 3 study of patients with active rheumatoid arthritis (RA) despite methotrexate (MTX) who were naive to biological therapy. METHODS: Patients were randomised to receive two infusions of placebo (n=63), rituximab 500 mg (n=62), or rituximab 1000 mg (n=60) intravenously on days 1 and 15. MRI scans and radiographs of the most inflamed hand and wrist were acquired at baseline, weeks 12 (MRI only), 24 and 52. The primary end point was the change in MRI erosion score from baseline at week 24. RESULTS: Patients treated with rituximab demonstrated significantly less progression in the mean MRI erosion score compared with those treated with placebo at weeks 24 (0.47, 0.18 and 1.60, respectively, p=0.003 and p=0.001 for the two rituximab doses vs placebo) and 52 (-0.30, 0.11 and 3.02, respectively; p<0.001 and p<0.001). Cartilage loss at 52 weeks was significantly reduced in the rituximab group compared with the placebo group. Other secondary end points of synovitis and osteitis improved significantly with rituximab compared with placebo as early as 12 weeks and improved further at weeks 24 and 52. CONCLUSIONS: This study demonstrated that rituximab significantly reduced erosion and cartilage loss at week 24 and week 52 in MTX-inadequate responder patients with active RA, suggesting that MRI is a valuable tool for assessing inflammatory and structural damage in patients with established RA receiving rituximab. TRIAL REGISTRATION NUMBER: NCT00578305.
650    _2
$a dospělí $7 D000328
650    _2
$a antirevmatika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x farmakoterapie $x patologie $x radiografie $7 D001172
650    _2
$a kloubní chrupavka $x patologie $7 D002358
650    _2
$a progrese nemoci $7 D018450
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rituximab $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000069283
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Emery, Paul $u Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
700    1_
$a Tak, Paul P $u *Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; *Current address also: University of Cambridge, Cambridge, UK and GlaxoSmithKline, Stevenage, UK.
700    1_
$a Østergaard, Mikkel $u Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital. University of Copenhagen, Copenhagen, Denmark.
700    1_
$a DiCarlo, Julie $u Spire Sciences, Inc., Boca Raton, Florida, USA.
700    1_
$a Otsa, Kati $u Tallinn Central Hospital, Tallinn, Estonia.
700    1_
$a Navarro Sarabia, Federico $u Hospital Universitario, Seville, Spain.
700    1_
$a Pavelka, Karel $u Charles University, Prague, Czech Republic.
700    1_
$a Bagnard, Marie-Agnes $u F Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Gylvin, Lykke Hinsch $u F Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Bernasconi, Corrado $u F Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Gabriele, Annarita $u F Hoffmann-La Roche Ltd, Basel, Switzerland.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 75, č. 1 (2016), s. 170-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25355728 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160725112833 $b ABA008
999    __
$a ok $b bmc $g 1155710 $s 945568
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 75 $c 1 $d 170-7 $e 20141029 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace